13:21:27 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-11-15 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-28 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-05-17 Ordinarie utdelning CLS B 0.00 SEK
2024-04-12 Extra Bolagsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-06-29 Årsstämma 2023
2023-06-22 Ordinarie utdelning CLS B 0.00 SEK
2023-06-08 Extra Bolagsstämma 2023
2023-05-25 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-22 Extra Bolagsstämma 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-29 Ordinarie utdelning CLS B 0.00 SEK
2022-06-28 Årsstämma 2022
2022-05-19 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-29 Ordinarie utdelning CLS B 0.00 SEK
2021-06-28 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-31 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning CLS B 0.00 SEK
2020-06-11 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-06-12 Ordinarie utdelning CLS B 0.00 SEK
2019-05-17 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-03-18 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-06-20 Årsstämma 2018
2018-06-14 Ordinarie utdelning CLS B 0.00 SEK
2018-05-24 Kvartalsrapport 2018-Q1
2018-05-18 Extra Bolagsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-07-17 Kvartalsrapport 2017-Q2
2017-06-28 Ordinarie utdelning CLS B 0.00 SEK
2017-06-27 Årsstämma 2017
2017-05-18 Kvartalsrapport 2017-Q1
2017-01-31 Bokslutskommuniké 2016
2017-01-20 Extra Bolagsstämma 2017
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-06-16 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-21 Bokslutskommuniké 2015
2015-11-19 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-06-12 Ordinarie utdelning CLS B 0.00 SEK
2015-06-11 Årsstämma 2015
2015-05-21 Kvartalsrapport 2015-Q1
2015-02-23 Bokslutskommuniké 2014
2014-11-14 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-06-18 Ordinarie utdelning CLS B 0.00 SEK
2014-06-17 Årsstämma 2014
2014-05-22 Kvartalsrapport 2014-Q1
2014-02-24 Bokslutskommuniké 2013
2013-11-22 Kvartalsrapport 2013-Q3
2013-09-19 Extra Bolagsstämma 2013
2013-08-20 Kvartalsrapport 2013-Q2
2013-06-10 Ordinarie utdelning CLS B 0.00 SEK
2013-06-07 Årsstämma 2013
2013-05-24 Kvartalsrapport 2013-Q1
2013-02-25 Bokslutskommuniké 2012
2012-11-23 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-06-08 Ordinarie utdelning CLS B 0.00 SEK
2012-06-07 Årsstämma 2012
2012-04-20 Kvartalsrapport 2012-Q1
2012-01-09 Bokslutskommuniké 2011
2012-01-04 Extra Bolagsstämma 2012
2011-11-21 Kvartalsrapport 2011-Q3
2011-09-26 Kapitalmarknadsdag 2010
2011-08-22 Kvartalsrapport 2011-Q2
2011-06-10 Årsstämma 2011
2011-05-20 Kvartalsrapport 2011-Q1
2011-02-24 Bokslutskommuniké 2010
2010-11-24 Kvartalsrapport 2010-Q3
2010-08-25 Kvartalsrapport 2010-Q2
2010-05-28 Ordinarie utdelning CLS B 0.00 SEK
2010-05-26 Kvartalsrapport 2010-Q1
2010-02-26 Bokslutskommuniké 2009
2009-11-30 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Clinical Laserthermia Systems är verksamt inom medicinteknik. Bolagets vision är att utveckla och effektivisera behandlingen av solida cancertumörer, där bolaget är försäljare av sterila patientkit. Produkterna används i diverse cancerbehandlingar som vid behandling av malignt melanom, samt cancer i lungor, lever och bukspottkörtel. Bolaget grundades 2006 och har sitt huvudkontor i Lund.
2022-05-12 13:00:00

CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced it will debut its Office-Based, MR/US Fusion-Guided, TRANBERG® Thermal Therapy System (https://clinicallaser.se/products/tranberg-thermal-therapy-system/) for high precision, focal laser ablation of soft tissue, such as prostate cancer tumors, at the upcoming AUA 2022 Conference being held May 13-16, 2022 in New Orleans.  The system is designed to work with multiple MR/US fusion image guidance systems for precise and accurate ablation in a minimally invasive setting, while preserving healthy prostate tissue. Focal therapies generally produce few side effects, such as erectile dysfunction and urinary incontinence. CLS Americas will be located in Booth #364.

In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men. These patients are demanding emergent therapies as alternatives to the standard treatments that have shown to carry long term harmful side effects.

"The AUA 2022 Annual Conference is the world's premier event for physicians, clinicians, and researchers to explore the latest advancements in urologic medicine," stated Michael Magnani, president of CLS Americas. "CLS is pleased to introduce its Office-Based, Fusion-Guided TRANBERG Thermal Therapy System at this year's conference. We believe there is significant patient need and market interest for an Office-Based, high precision focal laser ablation treatment of prostate tumors which also maximizes the preservation of healthy prostate tissue.  We are commercializing this innovative technology so that patients can benefit from being treated with focal laser ablation in a urology office or clinic instead of a hospital."

"While treating prostate cancer tumors successfully is the primary goal, some current treatment options expose patients to unacceptably high risks of complications such as erectile dysfunction or urinary incontinence," said Dr. Fernando J. Bianco, Investigator-In-Chief for the Urological Research Network, and Principle Investigator of the Phase I clinical study running at Urological Research Network, Miami Lakes. "Based on my initial clinical trial experience with the TRANBERG laser, I believe that partial gland fusion ablation provides the precision to successfully treat the cancerous lesions while offering patients a superior side effect profile. The ongoing study will provide us with more information on this."

CLS History & Experience - Image-Guided, Focal Laser Ablation of Prostate Tumors

CLS's TRANBERG® Thermal Therapy System has been used in hundreds of tumor laser ablation procedures in patients with localized prostate cancer in the US and EU using an in-bore, MRI-guided procedure. With the safety and diagnostic accuracy of MR/US fusion-guided transperineal prostate biopsy being well documented, this doctor's office procedure and technology are seeing a strong global adoption. Based on CLS's in-bore MR experience and by applying MR/US, fusion-guided transperineal procedures and technology to focal laser ablation performed with the TRANBERG® Thermal Therapy System, CLS is aiming at reducing the `focal therapy learning curve' and provide more patients the added benefit of a safe, fast and precise tumor ablation procedure.

CLS & URN Conducting US-Based, 20-Patient Clinical Study

CLS Americas and the Urological Research Network, LLC (https://research.surgery/), a Florida-based, not-for-profit clinical research organization are currently conducting a 20-patient, Phase I clinical study titled, "Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer."  The study utilizes CLS's TRANBERG System in combination with the Focalyx® Fusion (https://www.focalyx.com/en/focalyx-fusion) medical device for treatment planning, image fusion, and real-time image guidance during the high-precision, focal laser ablation treatment.  The first five patients have been enrolled in the study and successfully treated without any major safety issues.

The study is being performed by Dr. Fernando Bianco, a widely recognized pioneer of fusion target therapies in the office setting under local anesthesia and respected throughout the US and international medical community as an innovative urologic oncologist. He began his comprehensive MRI/US, Transperineal Fusion program in 2013 and has since performed over 2,500 biopsies and 1,000 fusion target cryoablations in the office setting.

High Precision Thermal Therapy System

The TRANBERG® Thermal Therapy System has been developed for image-guided, high-precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR, or MR/US fusion-guided procedures using tissue temperature feedback for precise therapy and ablation control. It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, external tissue temperature probe sensors, and procedure-specific accessories. The TRANBERG system can be deployed in either a transperineal or transrectal approach. Its non-cooled, laser fiber technology optimizes heat distribution, eliminates the need for external cooling and helps reduce procedure times.

About CLS and the TRANBERG® Product Portfolio

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including ThermoguideTM Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. All components of the TRANBERG® Thermal Therapy Systems have received EU-wide regulatory approval as medical devices (CE-marked class II) for the treatment of soft tissue lesions. CLS is developing its systems to get CE-mark class III for disposable TRANBERG laser applicators to be used in brain as well as expanding the current CE-mark for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal treatment effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: http://www.clinicallaser.se

###

The use of TRANBERG® Thermal Therapy System for immune stimulating interstitial laser thermotherapy (imILT®) and the ThermoguideTM thermometry software has not yet received market clearance by the Food and Drug Administration (FDA) in the United States of America (USA).

Company contact:
Clinical Laserthermia Systems AB
Dan J.Mogren, acting CEO
Tel: +46 - (0)705 - 90 11 40
E-mail: dan.mogren@clinicallaser.com

Company Contact:

CLS Americas:

Michael Magnani, President

T: +1 (949) 504-5440

E: michael.magnani@clinicallaser.com

Media Contact: CLS Americas

TopSpin Communications

Joe Waldygo, President

P: +1 (480)363-8774

E: joe@topspinpr.com